(Q33339749)

25 July 2017

1 reference

title

New aspects in the pathogenesis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (English)

1 reference

thrombotic thrombocytopenic purpura

25 July 2017

1 reference

1 reference

Raife T

1

1 reference

25 July 2017

Montgomery R

series ordinal

2

1 reference

25 July 2017

publication date

1 September 2001

1 reference

Reviews in Clinical and Experimental Hematology

25 July 2017

published in

1 reference

25 July 2017

volume

5

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

236-61; discussion 311-2

1 reference

Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Escherichia coliO157:H7 and the Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Hemolytic Uremic Syndromes in Childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Société de Néphrologie Pédiatrique

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Toxin-mediated haemolytic uraemic syndrome without diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Predictors for the development of haemolytic uraemic syndrome with Escherichia coli O157:H7 infections: with focus on the day of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Does blood type B protect against haemolytic uraemic syndrome? An analysis of the 1996 Sakai outbreak of Escherichia coli O157:H7 (VTEC O157) infection. The Osaka HUS Critical Care Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Induction of apoptosis in human renal proximal tubular epithelial cells by Escherichia coli verocytotoxin 1 in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Verotoxins induce apoptosis in human renal tubular epithelium derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Modulation of endothelial cell hemostatic properties by tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Death receptors: signaling and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Coagulation studies in the hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Clinical pharmacokinetics of ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Coagulation changes associated with the hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Plasminogen activator inhibitor type-1 and interleukin-6 in haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Human platelet aggregation is not altered by Shiga toxins 1 or 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Effect of TNF-alpha, Shiga toxin and calcium ionophore on Weibel-Palade body content of endothelial cells: possible implications for the hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Autosomal dominant hemolytic uremic syndrome: variable phenotypes and transplant results

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Genetic studies into inherited and sporadic hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Complement-mediated regulation of tissue factor activity in endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Staphylococcus aureus bacteremia as a cause of early relapse of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Isolation of a microtatobiote from patients with hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura and from mites in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

von Willebrand factor proteolysis and doxycycline in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

A western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Anti-CD36 antibodies in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Thrombotic thrombocytopenic purpura associated with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Thrombotic thrombocytopenic purpura related to ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Nucleotide receptors: an emerging family of regulatory molecules in blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Management of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Haemolytic-uraemic syndrome: basic science

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Activated platelet aggregates in thrombotic thromboctyopenic purpura: decrease with plasma infusions and normalization in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Von willebrand factor concentration, multimeric patterns, and cleaving protease activity in baboons undergoing xenogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

alpha 1-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Defibrotide in recurrent thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Recombinant fragment of von Willebrand factor AR545C inhibits platelet binding to thrombin and platelet adhesion to thrombin-treated endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Agkistin, a snake venom-derived glycoprotein Ib antagonist, disrupts von Willebrand factor-endothelial cell interaction and inhibits angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

Role of NFkappaB in the mortality of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00044.X

10.1046/J.1468-0734.2001.00044.X

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference